Riskpilot← Back to searchSign inGet full accesshameln pharma AB
ABActiveOrg 5593064438Gustavslundsvägen 143 5trWholesale of pharmaceutical and medical goods · NACE 4646Est. 20211 employees
Revenue 2024
SEK 20,2M
+2% vs 2023
EBITDA margin
35.7%
+21% vs 2023
Equity ratio
67.9%
Financial strength
Net profit 2024
SEK 5,7M
+22% vs 2023
| Revenue | SEK 20,2M | +2% |
| EBITDA | SEK 7,2M | +21% |
| Net profit | SEK 5,7M | +22% |
| Total assets | SEK 17,9M | +41% |
| Equity | SEK 12,2M | +88% |
| Employees | 1 | — |
Legal name
hameln pharma AB
Org number
5593064438
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10 mars 2021
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Grytberg, Per Jonas Jahrand, Frank Watkin, Stephen Allen
Company purpose
Bolaget ska registrera, importera, lagra och exportera, sälja, marknadsföra och distribuera läkemedel.
Address
Gustavslundsvägen 143 5tr
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 12 317 | 19 682 | 20 157 |
| Staff expenses | — | — | — | — |
| EBITDA | −1 291 | 1 867 | 5 952 | 7 195 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | −1 291 | 1 867 | 5 952 | 7 195 |
| Net financials | −1 | −29 | −55 | 3 |
| Profit before tax | −1 292 | 1 838 | 5 897 | 7 199 |
| Tax | −0 | −118 | −1 223 | −1 492 |
| Net profit | −1 292 | 1 720 | 4 674 | 5 707 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 254 | 7 829 | 12 722 | 17 914 |
| Equity | 58 | 1 779 | 6 452 | 12 159 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 195 | 6 050 | 6 270 | 5 755 |
| Total debt | 195 | 6 050 | 6 270 | 5 755 |
EBITDA margin
35.7%
This company
15.8%
Market median
+126% vs market
20212024
Equity ratio
67.9%
This company
38.2%
Market median
+78% vs market
20212024
Return on equity
46.9%
This company
18.4%
Market median
+155% vs market
20212024
Net profit margin
28.3%
This company
8.1%
Market median
+249% vs market
20212024
Asset turnover
1.13×
This company
1.12×
Market median
+1% vs market
20212024
Debt / equity
0.47×
This company
0.62×
Market median
+24% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-03-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LM Chief Auditor | Chief Auditor | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Former (3) | ||
| Deputy Board Member | 2021 – 2021 | |
| Deputy Board Member | 2021 – 2021 | |
| Board of Directors | 2021 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of hameln pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lajos Mathias Constantin Racz | Chief Auditor | 0 companies |
| Hans Jarl Rutger Arnhult | Deputy Board Member | 0 companies |
| Bo Daniel Falk | Deputy Board Member | 0 companies |
| Frank Jahrand | Chairman | 0 companies |
| Lars Anders Larsson | Board of Directors | 0 companies |
| Stephen Allen Watkin | Board of Directors | 0 companies |
| Per Jonas Grytberg | Board of Directors | 0 companies |